SURPASS-CVOT Explained: What the Tirzepatide Heart Outcomes Trial Found

SURPASS-CVOT is a large heart safety trial that asked whether tirzepatide is at least as safe for the heart as dulaglutide in people with type 2 diabetes and heart disease. CVOT stands for cardiovascular outcomes trial, a study designed to count heart attacks, strokes and deaths over several years.

Regulators ask drug makers to run these trials for diabetes medicines, because blood sugar control alone does not prove a drug is safe for the heart. Some older diabetes drugs raised heart risks, which is why the rule exists.

The trial chose dulaglutide (Trulicity) as the comparison on purpose. Dulaglutide is a weekly GLP-1 drug that was already shown to lower major heart events in the REWIND trial. That made it a tough comparison. Beating a placebo is one thing. Matching or beating a drug that already protects the heart is a higher bar.

The question matters for people using tirzepatide, which acts on two gut hormone receptors, GLP-1 and GIP. Weight loss and blood sugar results had looked excellent, as we covered in our review of [tirzepatide versus semaglutide](/blog/tirzepatide-vs-semaglutide-which-works-better-2026). Heart outcome data was the missing piece. SURPASS-CVOT adds it for people with diabetes.

The trial was a randomized, head-to-head study. Adults with type 2 diabetes and established atherosclerotic cardiovascular disease (plaque-related disease such as a past heart attack, stroke, or blocked leg or heart arteries) were assigned to tirzepatide or dulaglutide. They were followed for a median of about four years.

Tirzepatide was taken once weekly, at doses up to 15 mg. Dulaglutide was taken once weekly at 1.5 mg. Both groups also continued their usual diabetes and heart care, so the comparison reflects real-world treatment on top of standard medicines.

The main outcome was MACE-3, a shorthand for major adverse cardiovascular events. It counts the first occurrence of cardiovascular death, heart attack, or stroke. The trial first tested whether tirzepatide was non-inferior, meaning not meaningfully worse than dulaglutide. If that was met, it could then test for superiority.

This design is common in heart safety trials, and it explains why the results can look modest even when the drug is doing well. Non-inferiority is a safety goal, and a trial can pass it without proving the new drug is better. If you want a refresher on what hazard ratios and similar terms mean, our overview of [how GLP-1 drugs work](/blog/how-do-glp1-medications-actually-work-mechanism) is a good primer for the class.

Tirzepatide met its main goal. Major cardiovascular events occurred in about 12.2% of people on tirzepatide and 13.1% on dulaglutide, a hazard ratio of 0.92. A hazard ratio below 1 means fewer events, but here the confidence interval crossed 1, so the trial showed non-inferiority and not clear superiority.

In plain words, tirzepatide protected the heart about as well as a drug that already protects it, with a small edge that could have been chance. That is a good result for safety. It tells doctors and patients that the powerful weight and blood sugar effects of tirzepatide did not come with a hidden heart cost.

The all-cause death result is the one that stood out. People on tirzepatide had a 16% lower risk of dying from any cause, a hazard ratio of 0.84. This was a secondary outcome, so it should be read with some caution. Secondary results are less certain than the main one, because the trial was not built to prove them. Still, it points in a helpful direction.

Tirzepatide also lowered blood sugar and weight more than dulaglutide, which fits earlier SURPASS trials. Side effects were mainly stomach related, such as nausea and diarrhea, matching what we know from the GLP-1 class.

SURPASS-CVOT joins a growing list of GLP-1 heart trials, and each answers a slightly different question. The groups of people enrolled differ, so the results should not be lined up like a scoreboard.

SELECT (NEJM 2023) tested semaglutide 2.4 mg against placebo in about 17,600 adults with overweight or obesity and heart disease but no diabetes. Major events fell by 20% (hazard ratio 0.80). We summarize it in our article on [what SELECT found](/blog/glp1-heart-health-what-the-select-trial-found).

SOUL (NEJM 2025) tested oral semaglutide against placebo in about 9,650 people with type 2 diabetes and heart or kidney disease. Major events fell by 14% (hazard ratio 0.86). LEADER and REWIND showed benefits for liraglutide and dulaglutide in earlier years. FLOW showed kidney protection with semaglutide, which is covered in our piece on [the FLOW trial and kidney health](/blog/glp1-kidney-health-flow-trial-what-it-means).

The big difference is the comparison. Most earlier trials compared a drug with placebo. SURPASS-CVOT compared tirzepatide with another proven drug, so a hazard ratio near 1 is expected and is still a success for safety.

For people in midlife, the pattern across all of these trials is reassuring. The GLP-1 class, and now the dual GIP and GLP-1 drug, appear to do more than lower weight. They also appear to be safe for, and often helpful to, the heart. Our guide on [GLP-1 heart protection in menopause](/blog/glp1-menopause-heart-protection-cardiovascular-benefits) explains why that matters after the hormone shift.

Like every trial, SURPASS-CVOT has limits. The first is who was studied. Everyone had type 2 diabetes and established heart disease. The results do not directly tell us what tirzepatide does for the heart in someone with obesity but no diabetes, or in someone who has no heart disease yet.

That gap is being addressed by a separate trial called SURMOUNT-MMO, which is testing tirzepatide in adults with obesity and measuring heart and other major outcomes. Until it reports, doctors have to use the diabetes data as a hint, and not as proof, for people without diabetes.

The second limit is the comparison drug. Because dulaglutide already protects the heart, it is harder to show a gap between the two. A trial against placebo might have looked more dramatic. Do not read the modest hazard ratio as weak results.

Third, women were a minority in the trial, as in many heart studies, so we know less about differences by sex or by menopause status. Our overview of [what SWAN found about menopause and heart disease](/blog/menopause-heart-disease-risk-what-swan-found) explains why those details matter for midlife women.

Finally, a secondary result like the lower death rate needs confirmation. It is promising, but promising is not proven.

If you have type 2 diabetes and heart disease, SURPASS-CVOT is good news. It suggests tirzepatide is a safe choice for your heart and may offer extra benefits. If you already take it, there is no reason to change your treatment because of this trial.

If you have obesity without diabetes, the trial is more of an encouraging sign than an answer. Your doctor will weigh your own risks, such as blood pressure, cholesterol, family history and sleep apnea. Tirzepatide also improves many of those numbers, as shown in other trials.

There are practical points to remember. Keep taking your heart medicines, such as statins and blood pressure drugs, unless your doctor says otherwise. Weight loss can change the doses you need, so keep your regular checkups. Tell your care team if you notice chest pain, fainting, sudden breathlessness or a very fast heartbeat.

If you are comparing options, our review of [what is coming in the GLP-1 pipeline](/blog/next-gen-glp-1-pipeline-retatrutide-orforglipron-amycretin-2026) shows how newer drugs may build on this evidence. And if you want help preparing questions for your next visit, the tool below can help you draft them.

This article is for education and is not medical advice. Your prescriber knows your history best.

No medicine replaces the basics, and the basics are powerful. Blood pressure, cholesterol, blood sugar, sleep, movement and not smoking each shift your heart risk, and together they matter more than any single drug.

Aim for regular movement, such as brisk walking most days, plus strength training twice a week. Choose a mostly whole-food pattern with plenty of vegetables, beans, fish, nuts and olive oil. Keep alcohol low. Prioritize seven or more hours of sleep, and ask your doctor about sleep apnea if you snore or wake tired.

Know your numbers. Ask for blood pressure, LDL cholesterol, A1C and kidney function checks, and ask how often to repeat them. If you are over 40, ask whether a coronary calcium score or other risk tool makes sense for you.

And please know the heart symptoms women often describe. They can be less dramatic than the movie version: unusual fatigue, shortness of breath, nausea, jaw or back discomfort, or a sense that something is off. Do not wait it out. Call for help.

Taking care of your heart is not about perfection. It is about steady, kind habits and a team that listens.